Table 3.
Comparison of COVID-19 test status, incidence, and symptomatic status among users and nonusers of AYUSH measures. Percentages are calculated based on the total for each column.
| Characteristics | Total, n (%) | Respondents who were users of AYUSHa measures, n (%) | Respondents who were nonusers of AYUSH measures, n (%) | P valueb | |
| COVID-19 test status (n=408,089) | .67 | ||||
|
|
Tested | 27,661 (6.8) | 24,368 (6.8) | 3293 (6.8) |
|
|
|
Not tested | 380,428 (93.2) | 335,469 (93.2) | 44,959 (93.2) |
|
|
|
Total | 408,089 (100) | 359,837 (100) | 48,252 (100) |
|
| COVID-19 test result (n=27,661) | <.001 | ||||
|
|
Positive | 13,320 (48.2) | 12,002 (49.3) | 1318 (40.0) |
|
|
|
Negative | 14,341 (51.8) | 12,366 (50.7) | 1975 (60.0) |
|
|
|
Total | 27,661 (100) | 24,368 (100) | 3293 (100) |
|
| Symptomatic status of COVID-19 positive respondents (n=13,320) | <.001 | ||||
|
|
Asymptomatic | 8545 (64.2) | 8100 (67.6) | 445 (33.8) |
|
|
|
Symptomatic | 4775 (35.8) | 3902 (32.5) | 873 (66.2) |
|
|
|
Total | 13,320 (100) | 12,002 (100) | 1318 (100) |
|
| Risk category (n=408,089) | <.001 | ||||
|
|
In risk category | 19,757 (4.8) | 16,583 (4.6) | 3174 (6.6) |
|
|
|
Not in risk category | 388,332 (95.2) | 343,254 (95.4) | 45,078 (93.4) |
|
|
|
Total | 408,089 (100) | 359,837 (100) | 48,252 (100) |
|
| Comorbid conditions (n=408,089) | <.001 | ||||
|
|
Hypertension | 11,941 (2.9) | 10,638 (3.0) | 1303 (2.7) |
|
|
|
Asthma | 1089 (0.3) | 413 (0.1) | 676 (1.4) |
|
|
|
Diabetes mellitus | 2772 (0.7) | 2284 (0.6) | 488 (1.0) |
|
|
|
Heart disease | 1230 (0.3) | 992 (0.3) | 238 (0.5) |
|
|
|
Kidney disease | 671 (0.2) | 490 (0.1) | 181 (0.4) |
|
|
|
Cancer | 389 (0.1) | 234 (0.1) | 155 (0.3) |
|
|
|
Presence of multiple comorbid conditions | 9266 (2.3) | 8033 (2.2) | 1233 (2.5) |
|
|
|
None | 380,731 (93.3) | 336,753 (93.6) | 43,978 (91.2) |
|
aAYUSH: Ayurveda, yoga and naturopathy, Unani, Siddha, Sowa Rigpa, and homoeopathy.
bCompared using chi-square tests.